Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Melanoma Classification Using a Novel Deep Convolutional Neural Network with Dermoscopic Images
158
Zitationen
4
Autoren
2022
Jahr
Abstract
Automatic melanoma detection from dermoscopic skin samples is a very challenging task. However, using a deep learning approach as a machine vision tool can overcome some challenges. This research proposes an automated melanoma classifier based on a deep convolutional neural network (DCNN) to accurately classify malignant vs. benign melanoma. The structure of the DCNN is carefully designed by organizing many layers that are responsible for extracting low to high-level features of the skin images in a unique fashion. Other vital criteria in the design of DCNN are the selection of multiple filters and their sizes, employing proper deep learning layers, choosing the depth of the network, and optimizing hyperparameters. The primary objective is to propose a lightweight and less complex DCNN than other state-of-the-art methods to classify melanoma skin cancer with high efficiency. For this study, dermoscopic images containing different cancer samples were obtained from the International Skin Imaging Collaboration datastores (ISIC 2016, ISIC2017, and ISIC 2020). We evaluated the model based on accuracy, precision, recall, specificity, and F1-score. The proposed DCNN classifier achieved accuracies of 81.41%, 88.23%, and 90.42% on the ISIC 2016, 2017, and 2020 datasets, respectively, demonstrating high performance compared with the other state-of-the-art networks. Therefore, this proposed approach could provide a less complex and advanced framework for automating the melanoma diagnostic process and expediting the identification process to save a life.
Ähnliche Arbeiten
Dermatologist-level classification of skin cancer with deep neural networks
2017 · 13.516 Zit.
Tumor Angiogenesis: Therapeutic Implications
1971 · 10.113 Zit.
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
2011 · 7.675 Zit.
Pembrolizumab versus Ipilimumab in Advanced Melanoma
2015 · 5.811 Zit.
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
2017 · 5.364 Zit.